Active Ingredient History

  • Now
Buclizine, a piperazine derivative, is a sedating antihistamine with antimuscarinic and moderate sedative action. The drug is used mainly for its antiemetic action, particularly in the prevention of motion sickness, and in the treatment of migraine in combination with analgesics. The following side/adverse effects have been selected on the basis of their potential clinical significance: drowsiness; Incidence less frequent; blurred vision; dryness of mouth, nose, and throat; headache; nervousness, restlessness, or trouble in sleeping; upset stomach. The following drug interactions have been selected on the basis of their potential clinical significance: alcohol; anticholinergics or other medications with anticholinergic activity; apomorphine.   NCATS

More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Oral
  • Pro Drug: No
1-((4-chlorophenyl)phenylmethyl)-4-((4-(1,1-dimethylethyl)phenyl)methyl)piperazine | 1-(p-tert-butylbenzyl)-4-(4-chloro-alpha-phenylbenzyl)piperazine | aphilan | bucladin | bucladin-s | buclifen | buclizina | buclizine | buclizine dihydrochloride | buclizine hcl | buclizine hydrochloride | buclizinum | cyclizine hydrochloride | equivert | histabuticine | histabutizine | histabutyzine | hitabutyzyne | softran | stuart brand 1 of buclizine dihydrochloride | stuart brand 2 of buclizine dihydrochloride | ucb-4445


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue